Publications by authors named "Janet Dawson"

29Publications

Targeting interleukin-4 to the arthritic joint.

J Control Release 2020 Oct 10;326:172-180. Epub 2020 Jul 10.

Institute of Pharmacy and Food Chemistry, University of Würzburg, DE-97074 Würzburg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2020.07.005DOI Listing
October 2020

Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.

ACS Med Chem Lett 2019 Oct 6;10(10):1467-1472. Epub 2019 Sep 6.

Global Discovery Chemistry, Autoimmunity, Transplantation & Inflammation, Chemical Biology & Therapeutics, and PK Sciences, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.9b00317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792172PMC
October 2019

Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis.

Bioorg Med Chem 2017 08 29;25(16):4512-4525. Epub 2017 Jun 29.

Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2017.06.050DOI Listing
August 2017

Synthesis and Biological Evaluation of New Triazolo- and Imidazolopyridine RORγt Inverse Agonists.

ChemMedChem 2016 12 30;11(24):2640-2648. Epub 2016 Nov 30.

Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.201600500DOI Listing
December 2016

Erratum to: Palliative interventional pulmonology procedures in the incarcerated population with cancer: a case series.

Lung 2015 Apr;193(2):319

Interventional Pulmonology, Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University, PO Box 980050, Richmond, VA, 23298, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00408-015-9691-0
Publisher Site
http://dx.doi.org/10.1007/s00408-015-9691-0DOI Listing
April 2015

Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy.

J Allergy Clin Immunol 2013 Oct 14;132(4):959-68. Epub 2013 May 14.

Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2013.03.008DOI Listing
October 2013

In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.

Bioorg Med Chem Lett 2010 Aug 11;20(15):4719-23. Epub 2010 Apr 11.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2010.04.023DOI Listing
August 2010

Fluorescent nanoprobes as a biomarker for increased vascular permeability: implications in diagnosis and treatment of cancer and inflammation.

Bioconjug Chem 2010 Jan;21(1):93-101

Department of Autoimmunity, Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bc900311hDOI Listing
January 2010

Macrophage infiltration into the rat knee detected by MRI in a model of antigen-induced arthritis.

Magn Reson Med 2003 Jun;49(6):1047-55

Central Technologies, Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mrm.10480DOI Listing
June 2003

Targeting monocyte chemoattractant protein-1 signalling in disease.

Expert Opin Ther Targets 2003 Feb;7(1):35-48

Arthritis and Bone Metabolism Research, Novartis Pharma AG, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.7.1.35DOI Listing
February 2003

Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.

Bioorg Med Chem Lett 2002 Jan;12(2):233-5

Novartis Pharma AG, Arthritis & Bone Metabolism, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(01)00720-xDOI Listing
January 2002